| Medical and Health Sciences | 2021-2025 | 227 | AU 9 | 99.96 |
| Surgery | Lifetime | 247 | AU 14 | 99.79 |
| Cardiology and Cardiovascular Medicine | Lifetime | 250 | AU 9 | 99.67 |
| Medical Physiology | Lifetime | 963 | AU 37 | 98.16 |
| Surgery | 2021-2025 | 14 | AU 1 | 99.91 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 113 | AU 5 | 99.45 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 431 | AU 22 | 91.26 |
| Lipoproteins and Cardiovascular Health | Lifetime | 58 | AU 4 | 99.65 |
| Nitric Oxide and Endothelin Effects | Lifetime | 130 | AU 2 | 99.29 |
| Cardiac Imaging and Diagnostics | Lifetime | 437 | AU 5 | 99.27 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 388 | AU 11 | 99.03 |
| Coronary Interventions and Diagnostics | Lifetime | 379 | AU 5 | 98.89 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 268 | AU 7 | 98.66 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 396 | AU 14 | 98.62 |
| Cardiac Valve Diseases and Treatments | Lifetime | 751 | AU 13 | 98.55 |
| Cardiac Arrhythmias and Treatments | Lifetime | 667 | AU 12 | 98.36 |
| Acute Myocardial Infarction Research | Lifetime | 501 | AU 10 | 98.47 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 323 | AU 8 | 97.70 |
| Cardiovascular Health and Disease Prevention | Lifetime | 574 | AU 26 | 97.48 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 518 | AU 18 | 96.98 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 49 | AU 2 | 96.13 |
| Angiogenesis and VEGF in Cancer | Lifetime | 682 | AU 12 | 96.18 |
| Heart Failure Treatment and Management | Lifetime | 981 | AU 28 | 96.76 |
| Pharmaceutical Economics and Policy | Lifetime | 595 | AU 33 | 93.95 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 907 | AU 27 | 93.45 |
| Renin-Angiotensin System Studies | Lifetime | 746 | AU 31 | 94.00 |
| Nuclear Receptors and Signaling | Lifetime | 785 | AU 20 | 90.85 |
| Cardiac Fibrosis and Remodeling | Lifetime | 872 | AU 15 | 90.60 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 797 | AU 18 | 88.70 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 785 | AU 23 | 88.64 |
| GDF15 and Related Biomarkers | Lifetime | 416 | AU 17 | 84.15 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 20 | AU 2 | 99.16 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 24 | AU 3 | 99.46 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 176 | AU 4 | 98.58 |
| Acute Myocardial Infarction Research | 2021-2025 | 109 | AU 4 | 98.13 |
| Coronary Interventions and Diagnostics | 2021-2025 | 125 | AU 3 | 98.31 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 275 | AU 25 | 97.19 |
| Viral Infections and Immunology Research | 2021-2025 | 109 | AU 3 | 94.78 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 401 | AU 6 | 97.30 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 642 | AU 14 | 95.68 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 877 | AU 12 | 94.63 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 738 | AU 11 | 94.45 |
| Heart Failure Treatment and Management | 2021-2025 | 677 | AU 11 | 92.18 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 303 | AU 10 | 88.15 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 676 | AU 23 | 86.83 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 247 | AU 11 | 85.86 |
| Pharmaceutical Economics and Policy | 2021-2025 | 322 | AU 9 | 85.42 |
| Nuclear Receptors and Signaling | 2021-2025 | 132 | AU 2 | 81.95 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 810 | AU 20 | 85.21 |
| Cardiac Health and Mental Health | 2021-2025 | 889 | AU 65 | 81.87 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 899 | AU 9 | 76.51 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 241 | AU 3 | 72.51 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 972 | AU 11 | 59.09 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 580 | AU 30 | 57.05 |
